Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid Regurgitation

NCT ID: NCT05497141

Last Updated: 2022-08-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 98 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-22
• Study Completion Date: 2023-10-22

Brief Summary

To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve edge-to-edge repair system in patients with severe tricuspid regurgitation.

This is a prospective, multicenter, randomized, objective performance criteria trial. 98 patients who meet the inclusion criteria will be included in the study. This study will be conducted in in each site as run-in subjects. Subjects who meet the requirements and who voluntarily participate in the trial and sign the informed consent form, will be implanted with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.

Detailed Description

OBJECTIVES：To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve edge-to-edge repair system in patients with severe tricuspid regurgitation.

CLINICAL INVESTIGATION POPULATION:Patients who are on echocardiographic evidence of severe tricuspid regurgitation.

CLINICAL INVESTIGATION DESIGN:This is a prospective, multicenter, single arm, objective performance criteria trial. 98 patients who meet the inclusion criteria will be included in the study. This study will be conducted in in each site as run-in subjects. Subjects who meet the requirements and who voluntarily participate in the trial and sign the informed consent form, will be implanted with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.

Conditions

Tricuspid Regurgitation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

tricuspid valve edge-to edge Repair group

Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm

Group Type: EXPERIMENTAL

Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System

Intervention Type: DEVICE

Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.

Interventions

Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System

Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subjects of age > 18 years;

2. Subjects suffering from severe tricuspid regurgitation (TR≥3+), defined by TTE or TEE;

3. Subject has symptoms with NYHA ≥ Class II-Iva, or at least one hospitalization for symptoms of heart failure during the past 12 months.

4. Subjects with two cardiac surgeons agreements of contraindications to surgery or high risk, who meets at least one of the following three conditions:

① Euroscore≥8%；

② Presence of 2 or more Frailty Index；

③ Presence of 2 or more organ insufficiencies。

5. Subjects who's tricuspid valve anatomy are suitable for transcatheter valve edge-to-edge repairment as assessed.

6. Subjects agreeing to the scheduled follow up requirements, who can understand the purpose of the clinical investigation, and sign voluntarily the informed consent form by themselves and/or the subject' legal guardians.

Exclusion Criteria

1. Pulmonary artery systolic pressure >70 mmHg measured by transthoracic echocardiography or right heart catheterization, or irreversible precapillary pulmonary hypertension;

2. The presence of calcification in the grasping area of the tricuspid valve leaflets (including the anterior, septal, and posterior leaflets) that affects clamping, and the thickness of the tricuspid valve leaflets≥4mm;

3. Severe tricuspid leaflet perforation, cleft or other lesions which preventing the implantation;

4. Tricuspid valve leaflets coaptation gap >7mm

5. Tricuspid stenosis as assessed by echocardiography (defined as tricuspid orifice area ≤1.0 cm2)

6. LVEF≤20%；

7. Refractory heart failure requiring advanced intervention (e.g., left ventricular assist device, heart transplantation, etc.) (ACC/AHA stage D heart failure);

8. Myocardial infarction or unstable angina within 4 weeks;

9. Untreated severe coronary artery stenosis requiring revascularization;

10. Received percutaneous coronary intervention within 1 month prior to implantation;

11. Severe and uncontrolled hypertension: SBP≥180mmHg or DBP≥110mmHg;

12. Previously implantation of tricuspid valve, annuloplasty ring or accepted tricuspid valve repair surgery;

13. Pacemaker leads or ICD leads that may affect implantation

14. Complications of other cardiac diseases requiring surgical intervention;

15. Tricuspid leaflet lesions due to rheumatic heart disease (e.g., leaflet grossness, thickening, poor compliance, etc.);

16. Combined with moderate or severer aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation;

17. Congenital Ebstein malformation;

18. Presents of thrombus, vegetation, mass in the right heart system, femoral vein or inferior vena cava, etc.

19. Hemorrhagic disease or hypercoagulable state;

20. Contraindication or allergic reaction to dual antiplatelet agents and anticoagulants;

21. Active infection requiring antibiotic treatment;

22. Renal failure, requiring dialysis treatment;

23. Severe terminal illness (e.g., cancer, etc.) with a life expectancy of less than 1 year;

24. Pregnant, lactating women, women preparing to conceive or women of childbearing age with a positive HCG test (except for women whose medical history describes menopause);

25. Subjects have not met the observed endpoint in other clinical studies in which they participated;

26. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xiamen Cardiovascular Hospital, Xiamen University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yan Wang, Dr

Role: PRINCIPAL_INVESTIGATOR

Clinical Trial Center of Xiamen Cardiovascular Hospital

Nianguo Dong, Dr

Role: PRINCIPAL_INVESTIGATOR

Wuhan Xiehe Hospital

Locations

Xiamen Cardiovascular Hospital Xiamen University

Xiamen, Fujian, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiang Chen, Dr

Role: CONTACT

Seanchenx@126.com

18033997788

Facility Contacts

Yan Wang, Ph.D

Role: primary

wy@medmail.com.cn

Other Identifiers

2022YLK17

Identifier Type: -

Identifier Source: org_study_id